Two Studies Demonstrate REVLIMID(R) (lenalidomide) Activity In Patients With Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma

Celgene International Sarl (NASDAQ: CELG) announced that clinical data from two ongoing REVLIMID studies in Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma (NHL) were reported during the 49th Annual Meeting of the American Society of Hematology (ASH). These studies demonstrate REVLIMID’s activity in NHL and the need to further evaluate treatment in this critical area of blood disease. [click link for full article]

More: continued here

Filed under: Blood on December 15th, 2007